Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 247

Sort by

Sort Order Select

Journal Articles

Effects and Molecular Mechanism of Inhibiting p53 Signaling Pathway By NSUN6 on the Resistance to BCL-2 Inhibitor for Diffuse Large B-Cell Lymphoma

Yuanfei Shi, Yanchun Zhao, Yi Xu, Jianai Sun, Xiaolong Zheng, De Zhou, Jie Jin, Hongyan Tong, Wanzhuo Xie

Blood (2024) 144 (Supplement 1): 6238.

https://doi.org/10.1182/blood-2024-202205

Published: 2024

Journal Articles

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

Xuewu Zhang, Haitao Meng, Gaixiang Xu, Min Yang, Wanzhuo Xie, Juying Wei, Liya Ma, Xingnong Ye, Liping Mao, Wenyuan Mai, Chunmei Yang, Yanling Ren, Hongyan Tong, Yanan Zhu, Xiang Zhang, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6772.

https://doi.org/10.1182/blood-2024-203639

Published: 2024

Journal Articles

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Jianai Sun, Yi Xu, Huafeng Wang, Xiaolong Zheng, Wenjuan Yu, De Zhou, Chunmei Yang, Xinping Zhou, Liping Mao, Haitao Meng, Liangshun You, Min Yang, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2024) 144 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2024-197872

Published: 2024

Journal Articles

The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma

Yanan Zhu, Yunfei Lv, Xingnong Ye, Juying Wei, Lixia Sheng, Ying Lin, Xiang Zhang, Xuewu Zhang, Hongyan Tong, Jie Jin, Wen-Juan Yu

Blood (2024) 144 (Supplement 1): 1630.

https://doi.org/10.1182/blood-2024-198711

Published: 2024

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao

Blood (2024) 144 (Supplement 1): 477.

https://doi.org/10.1182/blood-2024-205300

Published: 2024

Journal Articles

Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia

Yinjun Lou, Jie Jin, Hongyan Tong, Shanshan Suo, Huafeng Wang, Liping Mao, Haitao Meng, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 1526.

https://doi.org/10.1182/blood-2024-209944

Published: 2024

Journal Articles

Integrating Spatial Transcriptome, Single-Cell Sequencing and Histopathology Reveals Bone Marrow Spatial Heterogenous in AML Patients

Xiangjie Lin, Huafeng Wang, Jie Jin

Blood (2024) 144 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2024-205328

Published: 2024

Journal Articles

Metabolic Signature of Oxidative Phosphorylation Deficiency with Activated Nucleotide Biosynthesis in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Yinghui Zhu, Bowen Wu, Tianyi Chen, Miaomiao Liu, Shangyu Hou, Xuemei Wang, Yiyi Yao, Tao Zeng, Jinyan Huang, Jie Jin, Huafeng Wang

Blood (2024) 144 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2024-205224

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2024-201210

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2024-201190

Published: 2024

Journal Articles

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Blood (2024) 144 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2024-199983

Published: 2024

Journal Articles

Remarkable Molecular Response in Patients with Polycythemia Vera Treated with Ropeginterferon Alfa-2b

Blood (2024) 144 (Supplement 1): 4562.

https://doi.org/10.1182/blood-2024-203148

Published: 2024

Journal Articles

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Chunmei Yang, Ying Lu, Juying Wei, Lihong Shou, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2024-200064

Published: 2024

Journal Articles

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Chunmei Yang, Juying Wei, Ying Lu, Liping Mao, Min Yang, Huafeng Wang, De Zhou, Hongyan Tong, Jie Jin, Wen-Juan Yu

Blood (2024) 144 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2024-203722

Published: 2024

Journal Articles

Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

Yafang Ma, Xiang Zhang, Jian Hou, Lijing Shen, Fei Li, Fancong Kong, Ying Lu, Guowei Li, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4280.

https://doi.org/10.1182/blood-2024-203359

Published: 2024

Journal Articles

Impact of Different Therapeutic Regimen on Prognosis in CEBPA bZIP-Inf Acute Myeloid Leukemia

Jiajia Pan, Nianci Chen, Liping Mao, Yinjun Lou, Yi Zhang, Shanshan Suo, Yile Zhou, Chenying Li, Xia Li, Xueying Yang, Qing Ling, Wenle Ye, Xiangjie Lin, Huafeng Wang, Jie Jin

Blood (2024) 144 (Supplement 1): 4274.

https://doi.org/10.1182/blood-2024-211698

Published: 2024

Journal Articles

Analysis of Risk Factors and Development of a Nomogram Prediction Model for Stem Cell Mobilization Failure in Lymphoma Patients

Qingqing Lin, Peipei Ye, Renzhi Pei, Jie Jin, Ying Lu

Blood (2024) 144 (Supplement 1): 5597.

https://doi.org/10.1182/blood-2024-204577

Published: 2024

Journal Articles

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

Blood (2024) 144 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2024-212216

Published: 2024

Journal Articles

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Lihong Shou, Qingchi Liu, Feng Zhang, Cuicui WU, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2024) 144 (Supplement 1): 3180.

https://doi.org/10.1182/blood-2024-210330

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

NARROW

Effects and Molecular Mechanism of Inhibiting p53 Signaling Pathway By NSUN6 on the Resistance to BCL-2 Inhibitor for Diffuse Large B-Cell Lymphoma

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia

Integrating Spatial Transcriptome, Single-Cell Sequencing and Histopathology Reveals Bone Marrow Spatial Heterogenous in AML Patients

Metabolic Signature of Oxidative Phosphorylation Deficiency with Activated Nucleotide Biosynthesis in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Remarkable Molecular Response in Patients with Polycythemia Vera Treated with Ropeginterferon Alfa-2b

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

Impact of Different Therapeutic Regimen on Prognosis in CEBPA bZIP-Inf Acute Myeloid Leukemia

Analysis of Risk Factors and Development of a Nomogram Prediction Model for Stem Cell Mobilization Failure in Lymphoma Patients

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only